Improvement of QoL for patients with Relapsed/Refractory Large B-Cell Lymphoma in CAR T-cell therapy
In this MEDtalk, Mahmoud Elsawy, MD, MSc, Queen Elizabeth II Health Sciences Centre and Dalhouse University, Canada, presents data from the ZUMA-7 study, the first randomized, global, multicenter Phase 3 study of axicabtagene Ciloleucel CAR T-cell therapy vs. standard of care treatment. The study shows a clinically meaningful improvement in QoL vs. standard of care at Day 100.
